<SEC-DOCUMENT>0001068238-23-000046.txt : 20230309
<SEC-HEADER>0001068238-23-000046.hdr.sgml : 20230309
<ACCEPTANCE-DATETIME>20230309103352
ACCESSION NUMBER:		0001068238-23-000046
CONFORMED SUBMISSION TYPE:	SC 13D
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20230309
DATE AS OF CHANGE:		20230309

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Carisma Therapeutics Inc.
		CENTRAL INDEX KEY:			0001485003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				262025616
		STATE OF INCORPORATION:			PA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-87951
		FILM NUMBER:		23718533

	BUSINESS ADDRESS:	
		STREET 1:		3675 MARKET STREET
		STREET 2:		SUITE 200
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
		BUSINESS PHONE:		2674916422

	MAIL ADDRESS:	
		STREET 1:		3675 MARKET STREET
		STREET 2:		SUITE 200
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Sesen Bio, Inc.
		DATE OF NAME CHANGE:	20180516

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Eleven Biotherapeutics, Inc.
		DATE OF NAME CHANGE:	20100223

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HealthCap VII, L.P.
		CENTRAL INDEX KEY:			0001645161
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D

	BUSINESS ADDRESS:	
		STREET 1:		18 AVENUE D'OUCHY
		CITY:			CH 1006 LAUSANNE
		STATE:			V8
		ZIP:			1000-1018
		BUSINESS PHONE:		41 21 614 3500

	MAIL ADDRESS:	
		STREET 1:		18 AVENUE D'OUCHY
		CITY:			CH 1006 LAUSANNE
		STATE:			V8
		ZIP:			1000-1018
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 13D
<SEQUENCE>1
<FILENAME>healthcap_sch13d.htm
<DESCRIPTION>HEALTHCAP SCHEDULE 13D
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: orrick herrington & sutcliffe
         Document created using EDGARfilings PROfile 8.4.0.0
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div><br>
  </div>
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div><br>
  </div>
  <div>
    <div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">UNITED STATES<br>
        SECURITIES AND EXCHANGE COMMISSION</div>
    </div>
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Washington, D.C. 20549</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Schedule&#160;13D</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Under the Securities Exchange Act of 1934</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">(Amendment No. __)*</div>
    <div>
      <div style="margin-bottom: 6pt;"><br>
      </div>
      <div style="text-align: center;">_______________________<br>
      </div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">CARISMA THERAPEUTICS INC.</div>
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(Name of Issuer)</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Common Stock, par value $0.001 per share</div>
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(Title of Class&#160;of Securities)</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">14216R 101</div>
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(CUSIP Number)</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">HealthCap VII, L.P.</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Represented by its general partner</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">HealthCap VII GP S.A.</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">23 Avenue Villamont</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Lausanne, V8 CH -1005</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">+4121 614 3500</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">(Name, Address and Telephone Number of Person</div>
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">Authorized to Receive Notices and Communications)</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">March 7, 2023</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">(Date of Event which Requires Filing of this Statement)</div>
    <div>
      <div style="margin-bottom: 12pt; text-align: center;">__________________________<br>
      </div>
      <div><br>
      </div>
    </div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">If the filing person has previously filed a statement on Schedule&#160;13G to report the acquisition that is the subject of this Schedule&#160;13D, and is filing
      this schedule because of &#167;240.13d-1(e), &#167;240.13d&#8209;1(f) or &#167;240.13d-1(g), check the following box: &#9633;</div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">* The remainder of this cover page shall be filled out for a reporting person&#8217;s initial filing on this form with respect to the subject class of
      securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.</div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">The information required on the remainder of this cover page&#160;shall not be deemed to be &#8220;filed&#8221; for the purpose of Section&#160;18 of the Securities Exchange
      Act of 1934, as amended (&#8220;<font style="font-weight: bold;">Act</font>&#8221;) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div>
      <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;"> <font style="font-weight: normal; font-size: 10pt;">Page 2 of 10</font><font style="font-size: 10pt;"><br>
        </font></div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;"> <font style="font-size: 10pt;"><br>
        </font></div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;"> <font style="font-size: 10pt;"><br>
        </font></div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">SCHEDULE&#160;13D</div>
    </div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">CUSIP No. 14216R 101</div>
    <table cellspacing="0" cellpadding="0" border="0" id="z6108b1f94f87481b8541bd209ca55741" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 13.04%; vertical-align: top; border-left: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="margin-left: 6.5pt; font-family: 'Times New Roman',Times,serif;">1.&#160;</div>
          </td>
          <td style="width: 86.96%; vertical-align: top; border-right: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);" colspan="4">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Name of Reporting Person</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.04%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 86.96%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);" colspan="4">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">HealthCap VII, L.P.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.04%; vertical-align: top; border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="margin-left: 6.5pt; font-family: 'Times New Roman',Times,serif;">2.</div>
          </td>
          <td style="width: 86.96%; vertical-align: top; border-right: 1px solid rgb(0, 0, 0);" colspan="4">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Check the Appropriate Box if a Member of a Group</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.04%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 14.96%; vertical-align: top; border-bottom: #000000 1px solid;">
            <div style="text-align: justify;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; width: 36pt;">&#160;</font><font style="font-family: 'Times New Roman',Times,serif;">&#9633;</font></div>
          </td>
          <td style="width: 72%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);" colspan="3">
            <div style="text-align: justify;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; width: 36pt;">&#160;</font><font style="font-family: 'Times New Roman',Times,serif;">&#9633;</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.04%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="margin-left: 6.5pt; font-family: 'Times New Roman',Times,serif;">3.</div>
          </td>
          <td style="width: 86.96%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);" colspan="4">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">SEC Use Only</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.04%; vertical-align: top; border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="margin-left: 6.5pt; font-family: 'Times New Roman',Times,serif;">4.</div>
          </td>
          <td style="width: 86.96%; vertical-align: top; border-right: 1px solid rgb(0, 0, 0);" colspan="4">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Source of Funds (See Instructions)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.04%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 86.96%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);" colspan="4">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">WC</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.04%; vertical-align: top; border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="margin-left: 6.5pt; font-family: 'Times New Roman',Times,serif;">5.</div>
          </td>
          <td style="width: 75.09%; vertical-align: top;" colspan="3">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Check if Disclosure of Legal Proceedings Is Required Pursuant to Items&#160;2(d) or 2(e)</div>
          </td>
          <td style="width: 11.88%; vertical-align: bottom; border-right: 1px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman',Times,serif;">&#9744;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.04%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 86.96%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);" colspan="4">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Not Applicable</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.04%; vertical-align: top; border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="margin-left: 6.5pt; font-family: 'Times New Roman',Times,serif;">6.</div>
          </td>
          <td style="width: 86.96%; vertical-align: top; border-right: 1px solid rgb(0, 0, 0);" colspan="4">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Citizenship or Place of Organization</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.04%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 86.96%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);" colspan="4">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Delaware</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.04%; vertical-align: middle; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);" rowspan="8">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">Number of Shares Beneficially Owned by Each Reporting Person With</div>
          </td>
          <td style="width: 16.83%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="font-family: 'Times New Roman',Times,serif;">7.</div>
          </td>
          <td style="width: 70.13%; vertical-align: top; border-right: 1px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Sole Voting Power</div>
          </td>
        </tr>
        <tr>
          <td style="width: 16.83%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="2">&#160;</td>
          <td style="width: 70.13%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">0</div>
          </td>
        </tr>
        <tr>
          <td style="width: 16.83%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">8.</div>
          </td>
          <td style="width: 70.13%; vertical-align: top; border-right: 1px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Shared Voting Power</div>
          </td>
        </tr>
        <tr>
          <td style="width: 16.83%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="2">&#160;</td>
          <td style="width: 70.13%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">3,579,611(1)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 16.83%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">9.</div>
          </td>
          <td style="width: 70.13%; vertical-align: top; border-right: 1px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Sole Dispositive Power</div>
          </td>
        </tr>
        <tr>
          <td style="width: 16.83%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="2">&#160;</td>
          <td style="width: 70.13%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">0</div>
          </td>
        </tr>
        <tr>
          <td style="width: 16.83%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">10.</div>
          </td>
          <td style="width: 70.13%; vertical-align: top; border-right: 1px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Shared Dispositive Power</div>
          </td>
        </tr>
        <tr>
          <td style="width: 16.83%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="2">&#160;</td>
          <td style="width: 70.13%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">3,579,611(1)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.04%; vertical-align: top; border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman',Times,serif;">11.</div>
          </td>
          <td style="width: 86.96%; vertical-align: top; border-right: 1px solid rgb(0, 0, 0);" colspan="4">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Aggregate Amount Beneficially Owned by Each Reporting Person</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.04%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 86.96%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);" colspan="4">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">3,579,611(1)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.04%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman',Times,serif;">12.</div>
          </td>
          <td style="width: 75.09%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0);" colspan="3">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Check if the Aggregate Amount in Row&#160;(11) Excludes Certain Shares</div>
          </td>
          <td style="width: 11.88%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">&#9633;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.04%; vertical-align: top; border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman',Times,serif;">13.</div>
          </td>
          <td style="width: 86.96%; vertical-align: top; border-right: 1px solid rgb(0, 0, 0);" colspan="4">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Percent of Class&#160;Represented by Amount in Row&#160;(11)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.04%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 86.96%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);" colspan="4">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">8.9%(2)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.04%; vertical-align: top; border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman',Times,serif;">14.</div>
          </td>
          <td style="width: 86.96%; vertical-align: top; border-right: 1px solid rgb(0, 0, 0);" colspan="4">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Type of Reporting Person</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.04%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 86.96%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);" colspan="4">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">PN</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 18pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(1) The number of shares of CARISMA Therapeutics Inc. (the &#8220;<font style="font-weight: bold;">Issuer</font>&#8221;)
      reported is based on the Issuer&#8217;s Registration Statement on Form S-4 filed with the Securities and Exchange Commission (&#8220;<font style="font-weight: bold;">SEC</font>&#8221;) on October 14, 2022, as amended by the Prospectus Supplement filed with the SEC on
      February 16, 2023, and the 1-for-20 reverse stock split effective at 5:01 p.m. Eastern Time on March 7, 2023, as reported on the Issuer&#8217;s Current Report on Form 8-K filed with the SEC on March 8, 2023.</div>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 18pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(2) As more fully described in the responses to Items 3 through 6 of this Schedule 13D, based on approximately
      40,254,672 shares of Common Stock of the Issuer (the &#8220;<font style="font-weight: bold;">Common Stock</font>&#8221;) outstanding as of March 7, 2023, the Reporting Person may be deemed to have beneficial ownership of 3,579,611 shares of Common Stock, which
      is equal to approximately 8.9% of the voting power of issued and outstanding Common Stock as of March 7, 2023.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div>
      <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;"> <font style="font-weight: normal; font-size: 10pt;">Page 3 of 10</font><font style="font-size: 10pt;"><br>
        </font></div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">SCHEDULE&#160;13D</div>
    </div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">CUSIP No. 14216R 101</div>
    <table cellspacing="0" cellpadding="0" border="0" id="z1f33a8891ec14c9b8cc0b38502f97333" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 13.42%; vertical-align: top; border-left: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="margin-left: 6.5pt; font-family: 'Times New Roman',Times,serif;">1.&#160;</div>
          </td>
          <td style="width: 86.58%; vertical-align: top; border-right: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);" colspan="4">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Name of Reporting Person</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.42%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 86.58%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);" colspan="4">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">HealthCap VII GP S.A.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.42%; vertical-align: top; border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="margin-left: 6.5pt; font-family: 'Times New Roman',Times,serif;">2.</div>
          </td>
          <td style="width: 86.58%; vertical-align: top; border-right: 1px solid rgb(0, 0, 0);" colspan="4">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Check the Appropriate Box if a Member of a Group</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.42%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 15.4%; vertical-align: top; border-bottom: #000000 1px solid;">
            <div style="text-align: justify;"><font style="font-family: 'Times New Roman',Times,serif;">(a)</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; width: 36pt;">&#160;</font><font style="font-family: 'Times New Roman',Times,serif;">&#9633;</font></div>
          </td>
          <td style="width: 71.18%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);" colspan="3">
            <div style="text-align: justify;"><font style="font-family: 'Times New Roman',Times,serif;">(b)</font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; width: 36pt;">&#160;</font><font style="font-family: 'Times New Roman',Times,serif;">&#9633;</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.42%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="margin-left: 6.5pt; font-family: 'Times New Roman',Times,serif;">3.</div>
          </td>
          <td style="width: 86.58%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);" colspan="4">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">SEC Use Only</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.42%; vertical-align: top; border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="margin-left: 6.5pt; font-family: 'Times New Roman',Times,serif;">4.</div>
          </td>
          <td style="width: 86.58%; vertical-align: top; border-right: 1px solid rgb(0, 0, 0);" colspan="4">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Source of Funds (See Instructions)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.42%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 86.58%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);" colspan="4">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">AF</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.42%; vertical-align: top; border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="margin-left: 6.5pt; font-family: 'Times New Roman',Times,serif;">5.</div>
          </td>
          <td style="width: 77.29%; vertical-align: top;" colspan="3">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Check if Disclosure of Legal Proceedings Is Required Pursuant to Items&#160;2(d) or 2(e)</div>
          </td>
          <td style="width: 9.28%; vertical-align: bottom; border-right: 1px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman',Times,serif;">&#9744;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.42%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 86.58%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);" colspan="4">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Not Applicable</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.42%; vertical-align: top; border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="margin-left: 6.5pt; font-family: 'Times New Roman',Times,serif;">6.</div>
          </td>
          <td style="width: 86.58%; vertical-align: top; border-right: 1px solid rgb(0, 0, 0);" colspan="4">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Citizenship or Place of Organization</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.42%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 86.58%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);" colspan="4">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Switzerland</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.42%; vertical-align: middle; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);" rowspan="8">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">Number of Shares Beneficially Owned by Each Reporting Person With</div>
          </td>
          <td style="width: 17.33%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="font-family: 'Times New Roman',Times,serif;">7.</div>
          </td>
          <td style="width: 69.25%; vertical-align: top; border-right: 1px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Sole Voting Power</div>
          </td>
        </tr>
        <tr>
          <td style="width: 17.33%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="2">&#160;</td>
          <td style="width: 69.25%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">0</div>
          </td>
        </tr>
        <tr>
          <td style="width: 17.33%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">8.</div>
          </td>
          <td style="width: 69.25%; vertical-align: top; border-right: 1px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Shared Voting Power</div>
          </td>
        </tr>
        <tr>
          <td style="width: 17.33%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="2">&#160;</td>
          <td style="width: 69.25%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">3,579,611(1)(2)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 17.33%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">9.</div>
          </td>
          <td style="width: 69.25%; vertical-align: top; border-right: 1px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Sole Dispositive Power</div>
          </td>
        </tr>
        <tr>
          <td style="width: 17.33%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="2">&#160;</td>
          <td style="width: 69.25%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">0</div>
          </td>
        </tr>
        <tr>
          <td style="width: 17.33%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">10.</div>
          </td>
          <td style="width: 69.25%; vertical-align: top; border-right: 1px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Shared Dispositive Power</div>
          </td>
        </tr>
        <tr>
          <td style="width: 17.33%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);" colspan="2">&#160;</td>
          <td style="width: 69.25%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">3,579,611(1)(2)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.42%; vertical-align: top; border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman',Times,serif;">11.</div>
          </td>
          <td style="width: 86.58%; vertical-align: top; border-right: 1px solid rgb(0, 0, 0);" colspan="4">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Aggregate Amount Beneficially Owned by Each Reporting Person</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.42%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 86.58%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);" colspan="4">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">3,579,611(1)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.42%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman',Times,serif;">12.</div>
          </td>
          <td style="width: 77.29%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0);" colspan="3">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Check if the Aggregate Amount in Row&#160;(11) Excludes Certain Shares</div>
          </td>
          <td style="width: 9.28%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">&#9633;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.42%; vertical-align: top; border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman',Times,serif;">13.</div>
          </td>
          <td style="width: 86.58%; vertical-align: top; border-right: 1px solid rgb(0, 0, 0);" colspan="4">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Percent of Class&#160;Represented by Amount in Row&#160;(11)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.42%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 86.58%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);" colspan="4">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">8.9%(3)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.42%; vertical-align: top; border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman',Times,serif;">14.</div>
          </td>
          <td style="width: 86.58%; vertical-align: top; border-right: 1px solid rgb(0, 0, 0);" colspan="4">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Type of Reporting Person</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.42%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 86.58%; vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);" colspan="4">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">OO</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 18pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(1) The number of shares of the Issuer reported is based on the Issuer&#8217;s Registration Statement on Form S-4 filed
      with the SEC on October 14, 2022, as amended by the Prospectus Supplement filed with the SEC on February 16, 2023, and the 1-for-20 reverse stock split effective at 5:01 p.m. Eastern Time on March 7, 2023, as reported on the Issuer&#8217;s Current Report
      on Form 8-K filed with the SEC on March 8, 2023.</div>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 18pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(2)&#160; HealthCap VII GP SA, a corporation organized under the laws of Switzerland, is the sole general partner of
      HealthCap VII, L.P. and has voting and investment control over the shares. HealthCap VII GP SA disclaims beneficial ownership of all shares held by HealthCap VII L.P., except to the extent of their pecuniary interest therein.</div>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 18pt; margin-bottom: 12pt;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: right; text-indent: -18pt; margin-left: 18pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;"> Page 4 of 10<br>
    </div>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 18pt; margin-bottom: 12pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 18pt; margin-bottom: 12pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: -18pt; margin-left: 18pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(3) As more fully described in the responses to Items 3 through 6 of this Schedule 13D, based on approximately
      40,254,672 shares of Common Stock outstanding as of March 7, 2023, the Reporting Person may be deemed to have beneficial ownership of 3,579,611 shares of Common Stock, which is equal to approximately 8.9% of the voting power of issued and outstanding
      Common Stock as of March 7, 2023.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: right; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;"> <font style="font-weight: normal; font-size: 10pt;">Page 5 of 10</font><font style="font-size: 10pt;"><br>
      </font></div>
    <div style="text-align: justify; margin-bottom: 12pt; font-size: 12pt; font-weight: bold;"> <font style="font-size: 10pt;"><br>
      </font></div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Item 1. Security and Issuer</div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">This Schedule 13D (this &#8220;<font style="font-weight: bold;">Schedule 13D</font>&#8221;) relates to shares of common stock, $0.001 par value per share (the &#8220;<font style="font-weight: bold;">Common Stock</font>&#8221;), of CARISMA Therapeutics Inc., a Delaware corporation (the &#8220;<font style="font-weight: bold;">Issuer</font>&#8221;).&#160; The Issuer&#8217;s principal executive offices are located at 245 First Street, Suite 1800,
      Cambridge, MA 02142.</div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Item 2. Identity and Background</div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">This Schedule 13D is being filed by the following persons (each a &#8220;<font style="font-weight: bold;">Reporting Person</font>&#8221; and together the &#8220;<font style="font-weight: bold;">Reporting Persons</font>&#8221;):</div>
    <div>
      <table cellspacing="0" cellpadding="0" id="za40b3721faf84fef90251b004aede114" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top;">
              <div style="margin-left: 18pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">1.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">HealthCap VII, L.P., a Delaware limited partnership (the &#8220;<font style="font-weight: bold;">Fund</font>&#8221;); and</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z3222e9d16afb48e9bbc4b2a2a030081d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top;">
              <div style="margin-left: 18pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">2.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">HealthCap VII GP S.A., a corporation organized under the laws of Switzerland (the &#8220;<font style="font-weight: bold;">General Partner</font>&#8221;),
                which is the sole general partner of the Fund.</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">The principal business address of each Reporting Person is c/o HealthCap VII GP S.A., 23 Avenue Villamont, Lausanne, Switzerland CH 1005. The principal
      business of the Reporting Persons and the Managers (as defined below) is venture capital investment focused on the health care sector.</div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">During the last five years, none of the Reporting Persons or the Managers has been convicted in a criminal proceeding (excluding traffic violations or
      similar misdemeanors).</div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">During the last five years, none of the Reporting Persons or the Managers has been party to a civil proceeding of a judicial or administrative body of
      competent jurisdiction and as a result of such proceeding were or are subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any
      violation with respect to such laws.</div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">The Reporting Persons have entered into a Joint Filing Agreement, dated as of the date hereof, a copy of which is filed with this Schedule 13D as Exhibit
      1.01, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k) under the Act.</div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Item 3. Source and Amount of Funds or Other Consideration.</div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">As more fully described in Items 4 and 6 below, on September 20, 2022, Sesen Bio, Inc., a Delaware corporation (&#8220;<font style="font-weight: bold;">Sesen
        Bio</font>&#8221;), Seahawk Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Sesen Bio (&#8220;<font style="font-weight: bold;">Merger Sub</font>&#8221;), and CARISMA Therapeutics Inc., a Delaware corporation (&#8220;<font style="font-weight: bold;">Carisma</font>&#8221;), entered into an Agreement and Plan of Merger and Reorganization (as amended from time to time, the &#8220;<font style="font-weight: bold;">Merger Agreement</font>&#8221;), pursuant to which, among other things, and subject to the
      satisfaction or waiver of certain conditions set forth in the Merger Agreement, Merger Sub merged with and into Carisma, with Carisma continuing as a wholly-owned subsidiary of Sesen Bio and the surviving corporation of the merger (the &#8220;<font style="font-weight: bold;">Merger</font>&#8221;). At the effective time of the Merger, Sesen Bio filed an amendment to its certificate of incorporation, to change its name to &#8220;CARISMA Therapeutics Inc.&#8221;</div>
    <div style="text-align: justify; margin-bottom: 12pt; font-size: 12pt;"> <font style="font-size: 10pt;"><br>
      </font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: right; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt;"> <font style="font-size: 10pt;">Page 6 of 10<br>
      </font></div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">Prior to the Merger, the Fund owned 1,485,912 of Carisma&#8217;s capital stock, consisting of (i) 250,647 shares of Carisma common stock issuable upon
      conversion of the Carisma Series A preferred stock (&#8220;<font style="font-weight: bold;">Series A Conversion Shares</font>&#8221;), acquired pursuant to the Series A Preferred Stock Purchase Agreement, dated June 26, 2018, by and among Carisma, CARISMA
      Therapeutics S.&#224; r.l., a <font style="font-style: italic;">soci&#233;t&#233; &#224; responsabilit&#233; limit&#233;e</font> organized under the laws of Luxembourg, and the investors listed therein, including the Fund (the &#8220;<font style="font-weight: bold;">Series A SPA</font>&#8221;),



      (ii) 937,501 shares of Carisma common stock issuable upon the conversion of the Carisma special voting preferred stock (&#8220;<font style="font-weight: bold;">Special Voting Conversion Share</font>s&#8221;), acquired pursuant to the Series A SPA, and (iii)
      297,764 shares of Carisma common stock issuable upon the conversion of the Carisma Series B special voting preferred stock (&#8220;<font style="font-weight: bold;">Series B Conversion Shares</font>,&#8221; and together with Series A Conversion Shares and Special
      Voting Conversion Shares, collectively, the &#8220;<font style="font-weight: bold;">Pre-Merger Carisma Shares</font>&#8221;), acquired pursuant to the Series B Preferred Stock Purchase Agreement, dated December 22, 2020, by and among Carisma, CARISMA
      Therapeutics S.&#224; r.l., a <font style="font-style: italic;">soci&#233;t&#233; &#224; responsabilit&#233; limit&#233;e</font> organized under the laws of Luxembourg, and the investors listed therein, including the Fund (the &#8220;<font style="font-weight: bold;">Series B SPA</font>&#8221;),



      held by the Fund. The Pre-Merger Carisma Shares were acquired by the Fund using funds obtained from working capital.</div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">Pursuant to the Merger Agreement, upon the effectiveness of the Merger, each outstanding Pre-Merger Carisma Share was converted into the right to receive
      a number of shares of Sesen Bio common stock calculated in accordance with the Merger Agreement. Cash was paid in lieu of fractional shares. Accordingly, the Fund now owns 3,579,611 shares of the common stock of the combined company.</div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">The foregoing references to and descriptions of the Merger Agreement and the transactions contemplated thereby, do not purport to be complete and are
      subject to, and are qualified in their entirety by reference to, the full text of the Merger Agreement, attached hereto as Exhibits 1.02-1.04 to include its amendments.</div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Item 4.&#160; Purpose of Transaction.</div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">The Fund acquired the shares of Common Stock for investment purposes.</div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors, including but not limited to
      the Issuer&#8217;s financial position and strategic direction, price levels of its Common Stock, conditions in the securities markets, and general economic and industry conditions, the Reporting Persons may take actions with respect to their investment in
      the Issuer. These actions include changing their current investment purpose and/or, from time to time, (i) acquiring or causing affiliates to acquire additional shares in open market transactions, in privately negotiated transactions or through other
      methods; (ii) disposing or causing affiliates to dispose of some or all of the shares in open market transactions, in privately negotiated transactions or through other methods, including distributions by the Fund directly to its limited partners; or
      (iii) continuing to hold or causing affiliates to hold the shares (or any combination or derivative thereof). In addition, the Reporting Persons may engage in discussions with the Issuer&#8217;s management, members of its board of directors, stockholders
      and other relevant parties or take other actions concerning the Issuer&#8217;s operations, capital expenditures, financings, executive compensation practices, capital structure and any matter set forth in paragraphs (a) through (j) of Item 4 of Schedule
      13D.</div>
    <div style="text-align: justify; margin-bottom: 12pt; font-size: 12pt;"> <font style="font-size: 10pt;"><br>
      </font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: right; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt;"> <font style="font-size: 10pt;">Page 7 of 10<br>
      </font></div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">The information set forth in Item 6 is incorporated by reference in its entirety into this Item 4.</div>
    <div style="text-align: justify; margin-bottom: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Item&#160;5.&#160;&#160; Interest in Securities of the Issuer.</font></div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(a)-(b) The information set forth in rows 7 through 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in
      row 13 is based on approximately 40,254,672 shares of Common Stock outstanding as of March 7, 2023, as reported in the Issuer&#8217;s Current Report on Form 8-K filed with the SEC on March 8, 2023.</div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">The Fund directly holds 3,579,611 shares of Common Stock. As the sole general partner of the Fund, the General Partner may be deemed to beneficially own
      the shares held by the Fund. Fabrice Bernhard serves as an executive officer of the General Partner, and each of Dag Richter, Daniel Schafer, and Frans Wuite (together with Mr. Bernhard, the &#8220;<font style="font-weight: bold;">Managers</font>&#8221;) serves
      as a director of the General Partner.</div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(c) Except as described in this Schedule 13D, there have been no transactions in the shares of Common Stock effected by the Reporting Persons, or to the
      best of the Reporting Persons&#8217; knowledge, the Managers, during the last 60 days.</div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(d) Except as described herein, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the
      sale of, securities covered by this statement.</div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(e) Not applicable.</div>
    <div style="text-align: justify; margin-bottom: 12pt;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Item&#160;6.</font>&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Contracts, Arrangements,
        Understandings or Relationships with Respect to Securities of the Issuer.</font></div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-style: italic; font-weight: bold;">Support Agreement and Lock-Up Agreement</div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">Concurrently with the execution of the Merger Agreement, (a) certain stockholders of Carisma (solely in their respective capacities as Carisma
      stockholders) holding approximately 97.83% of the outstanding shares of Carisma capital stock (subject to customary cutbacks in the event of certain triggering events by the Sesen Bio board of directors) entered into support agreements with Sesen Bio
      and Carisma to vote, among other things, all of their shares of Carisma capital stock in favor of adoption of the Merger Agreement and the transactions contemplated thereby, and against any alternative acquisition proposals (the &#8220;<font style="font-weight: bold;">Carisma Support Agreements</font>&#8221;).</div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">Concurrently with the execution of the Merger Agreement, certain executive officers, directors and stockholders of Sesen Bio and Carisma (solely in their
      respective capacities as stockholders) have entered into lock-up agreements (the &#8220;<font style="font-weight: bold;">Lock-Up Agreements</font>&#8221;) pursuant to which, subject to specified exceptions, they agreed not to transfer their shares of the
      Issuer&#8217;s common stock issued in connection with the Merger for the 180-day period following the closing of the Merger.</div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">The preceding summaries of the Carisma Support Agreements and the Lock-Up Agreements do not purport to be complete and are subject to, and are qualified
      in their entirety by reference to, the full text of the form of Carisma Support Agreement and the form of Lock-Up Agreement, attached hereto as Exhibits 1.05 and 1.06, respectively, and incorporated herein by reference.</div>
    <div style="text-align: justify; margin-bottom: 12pt; font-size: 12pt;"> <font style="font-size: 10pt;"><br>
      </font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: right; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt;"> <font style="font-size: 10pt;">Page 8 of 10<br>
      </font></div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">Except as set forth in this Item 6, to the best of the Reporting Persons&#8217; knowledge, there are no contracts, arrangements, understandings or
      relationships (legal or otherwise), among the Reporting Persons or the Managers, or between such persons and any person with respect to any securities of the Issuer (including any securities pledged or otherwise subject to a contingency the
      occurrence of which would give another person voting power or investment power over such securities other than standard default and similar provisions contained in loan agreements), including, but not limited to, transfer or voting of any shares of
      the Common Stock, finder&#8217;s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.</div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Item&#160;7.&#160; Material to be Filed as Exhibits.</div>
    <table cellspacing="0" cellpadding="0" id="z9837400090584083ac1e4a75c4045ba5" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 8.61%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">1.01</div>
          </td>
          <td style="width: 91.39%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;"><a href="#ex101">Joint Filing Agreement, dated as of March 9, 2023, by and among the Reporting Persons.</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.61%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 91.39%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 8.61%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">1.02</div>
          </td>
          <td style="width: 91.39%; vertical-align: top;">
            <div style="text-align: justify; color: rgb(5, 99, 193); font-family: 'Times New Roman',Times,serif;"><a href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000135/exhibit21-projectseahawkxm.htm"><u>Agreement and Plan of Merger
                  and Reorganization, dated as of September 20, 2022, by and among </u><u>Sesen Bio, Inc., Seahawk Merger Sub, Inc. and CARISMA Therapeutics Inc. </u><u>(incorporated by reference to Exhibit 2.1 to Sesen Bio, Inc.&#8217;s Current Report on Form
                  8-K filed with the SEC on September 21, 2022).</u></a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.61%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 91.39%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 8.61%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">1.03</div>
          </td>
          <td style="width: 91.39%; vertical-align: top;">
            <div style="text-align: justify; color: rgb(5, 99, 193); font-family: 'Times New Roman',Times,serif;"><a href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000182/projectseahawk-firstamen.htm"><u>First Amendment to Agreement and
                  Plan of Merger and Reorganization, dated as of December 29, 2022, by and among Sesen Bio, Inc., Seahawk Merger Sub, Inc., and CARISMA Therapeutics, Inc. </u><u>(incorporated by reference to Exhibit 2.1 to Sesen Bio, Inc.&#8217;s Current Report
                  on Form 8-K filed with the SEC on December 29, 2022).</u></a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.61%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 91.39%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 8.61%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">1.04</div>
          </td>
          <td style="width: 91.39%; vertical-align: top;">
            <div style="text-align: justify; color: rgb(5, 99, 193); font-family: 'Times New Roman',Times,serif;"><a href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923020879/tm236507d1_ex2-1.htm">Second Amendment to Agreement and Plan of
                Merger and Reorganization, dated as of February 13, 2023, by and among Sesen Bio, Inc., Seahawk Merger Sub, Inc., and CARISMA Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 to Sesen Bio, Inc.&#8217;s Current Report on Form 8-K filed
                with the SEC on February 14, 2023).</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.61%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 91.39%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 8.61%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">1.05</div>
          </td>
          <td style="width: 91.39%; vertical-align: top;">
            <div style="text-align: justify; color: rgb(5, 99, 193); font-family: 'Times New Roman',Times,serif;"><a href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000135/exhibit102-formofcompanyst.htm">Form of Company Stockholder
                Support Agreement (incorporated by reference to Exhibit 10.2 to Sesen Bio, Inc.&#8217;s Current Report on Form 8-K filed with the SEC on September 21, 2022).</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.61%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 91.39%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 8.61%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">1.06</div>
          </td>
          <td style="width: 91.39%; vertical-align: top;">
            <div style="text-align: justify; color: rgb(5, 99, 193); font-family: 'Times New Roman',Times,serif;"><a href="https://www.sec.gov/Archives/edgar/data/1485003/000148500322000135/exhibit104-formoflockxupag.htm">Form of Lock-Up Agreement
                (incorporated by reference to Exhibit 10.4 to Sesen Bio, Inc.&#8217;s Current Report on Form 8-K filed with the SEC on September 21, 2022).</a></div>
          </td>
        </tr>

    </table>
    <div style="margin-bottom: 12pt;"><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: right;">Page 9 of 10<br>
    </div>
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">SIGNATURES</div>
    <div style="text-align: justify; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">After reasonable inquiry and to the best of its knowledge and belief,&#160;the undersigned hereby certify that the information set forth in
      this statement is true, complete and correct.</div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">Date: March 9, 2023</div>
    <div style="text-align: justify; margin-left: 252pt; font-family: 'Times New Roman',Times,serif;">HEALTHCAP VII, L.P.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 252pt; font-family: 'Times New Roman',Times,serif;">By its general partner HealthCap VII GP SA</div>
    <div><br>
    </div>
    <div style="margin-left: 252pt;"><font style="font-family: 'Times New Roman',Times,serif;">By: <u>/s/ Dag Richter &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;</u><u>&#160; </u></font></div>
    <div style="text-align: justify; margin-left: 252pt; font-family: 'Times New Roman',Times,serif;">Name: Dag Richter</div>
    <div style="text-align: justify; margin-left: 252pt; font-family: 'Times New Roman',Times,serif;">Title:&#160;&#160; Director</div>
    <div><br>
    </div>
    <div style="margin-left: 252pt;"><font style="font-family: 'Times New Roman',Times,serif;">By: <u>/s/ Fabrice Bernhard &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;</u><u>&#160; </u></font></div>
    <div style="text-align: justify; margin-left: 252pt; font-family: 'Times New Roman',Times,serif;">Name: Fabrice Bernhard</div>
    <div style="text-align: justify; margin-left: 252pt; font-family: 'Times New Roman',Times,serif;">Title:&#160;&#160; General Manager</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 252pt; font-family: 'Times New Roman',Times,serif;">HEALTHCAP VII GP SA</div>
    <div><br>
    </div>
    <div style="margin-left: 252pt;"><font style="font-family: 'Times New Roman',Times,serif;">By: <u>/s/ Dag Richter &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;</u><u> </u></font></div>
    <div style="text-align: justify; margin-left: 252pt; font-family: 'Times New Roman',Times,serif;">Name: Dag Richter</div>
    <div style="text-align: justify; margin-left: 252pt; font-family: 'Times New Roman',Times,serif;">Title:&#160;&#160; Director</div>
    <div><br>
    </div>
    <div style="margin-left: 252pt;"><font style="font-family: 'Times New Roman',Times,serif;">By: <u>/s/</u><u>Fabrice Bernhard &#160; &#160;&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;</u><u> </u></font></div>
    <div style="text-align: justify; margin-left: 252pt; font-family: 'Times New Roman',Times,serif;">Name: Fabrice Bernhard</div>
    <div style="text-align: justify; margin-left: 252pt; font-family: 'Times New Roman',Times,serif;">Title:&#160;&#160; General Manager</div>
    <div><br>
    </div>
    <div style="margin-bottom: 12pt;"><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: right; margin-left: 216pt; font-family: 'Times New Roman',Times,serif;">&#160;<font style="font-weight: bold;"><a name="ex101"><!--Anchor--></a>Exhibit 1.01</font></div>
    <div>
      <div><br>
      </div>
      <div style="text-align: center; margin-top: 12pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">JOINT FILING AGREEMENT</div>
    </div>
    <div>
      <div><br>
      </div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">The undersigned hereby agree that they are filing this statement on Schedule&#160;13D jointly pursuant to Rule&#160;13d-1(k)(1). Each of them is responsible for the
      timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information
      concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">In accordance with Rule&#160;13d-1(k)(1)&#160;promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing
      with each other on behalf of each of them of such a statement on Schedule 13D with respect to the Common Stock, par value $0.001 per share, of CARISMA Therapeutics, Inc., a Delaware corporation, beneficially owned by each of them. This Joint Filing
      Agreement shall be included as an exhibit to such Schedule 13D.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement as of the 9th day of March, 2023.</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; margin-left: 252pt; font-family: 'Times New Roman',Times,serif;">HEALTHCAP VII, L.P.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 252pt; font-family: 'Times New Roman',Times,serif;">By its general partner HealthCap VII GP SA</div>
    <div><br>
    </div>
    <div style="margin-left: 252pt;"><font style="font-family: 'Times New Roman',Times,serif;">By: <u>/s/ Dag Richter &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;</u><u>&#160; </u></font></div>
    <div style="text-align: justify; margin-left: 252pt; font-family: 'Times New Roman',Times,serif;">Name: Dag Richter</div>
    <div style="text-align: justify; margin-left: 252pt; font-family: 'Times New Roman',Times,serif;">Title:&#160;&#160; Director</div>
    <div><br>
    </div>
    <div style="margin-left: 252pt;"><font style="font-family: 'Times New Roman',Times,serif;">By: <u>/s/ Fabrice Bernhard &#160; &#160; &#160; &#160; &#160; &#160;</u></font> &#160; &#160; &#160; &#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><u> </u></font></div>
    <div style="text-align: justify; margin-left: 252pt; font-family: 'Times New Roman',Times,serif;">Name: Fabrice Bernhard</div>
    <div style="text-align: justify; margin-left: 252pt; font-family: 'Times New Roman',Times,serif;">Title:&#160;&#160; General Manager</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 252pt; font-family: 'Times New Roman',Times,serif;">HEALTHCAP VII GP SA</div>
    <div><br>
    </div>
    <div style="margin-left: 252pt;"><font style="font-family: 'Times New Roman',Times,serif;">By: <u>/s/ Dag Richter &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;</u></font><font id="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; width: 216pt;"> </font><font style="font-family: 'Times New Roman',Times,serif;"><u>&#160; </u></font></div>
    <div style="text-align: justify; margin-left: 252pt; font-family: 'Times New Roman',Times,serif;">Name: Dag Richter</div>
    <div style="text-align: justify; margin-left: 252pt; font-family: 'Times New Roman',Times,serif;">Title:&#160;&#160; Director</div>
    <div><br>
    </div>
    <div style="margin-left: 252pt;"><font style="font-family: 'Times New Roman',Times,serif;">By: <u>/s/</u><u>Fabrice Bernhard &#160; &#160; &#160; &#160; &#160; &#160; &#160;</u><u> </u></font></div>
    <div style="text-align: justify; margin-left: 252pt; font-family: 'Times New Roman',Times,serif;">Name: Fabrice Bernhard</div>
    <div style="text-align: justify; margin-left: 252pt; font-family: 'Times New Roman',Times,serif;">Title:&#160;&#160; General Manager</div>
    <div><br>
    </div>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div>
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
